SCHEMBL14728720

SCHEMBL14728720

COCCc1cc(C(N)=O)c2nc3ccccc3n2c1N1CCC(CO)(OC)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.61
ALDH1A1 P00352 8/20 0.37
HPGD P15428 5/20 0.37
CASP1 P29466 4/20 0.37
HSD17B10 Q99714 3/20 0.37
CASP7 P55210 3/20 0.37
TSHR P16473 2/20 0.37
KDM4E B2RXH2 9/20 0.35
GAA P10253 3/20 0.35
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
EGFR P00533 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ROCK2 O75116 1/20 0.32
POLB P06746 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
PKM P14618 1/20 0.31
MAPK1 P28482 1/20 0.31
MAPT P10636 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14728725 0.88 PDE4B (0.61) PDE4BALDH1A1HPGDCASP1HSD17B10
SCHEMBL14728713 0.86 PDE4B (0.65) PDE4BALDH1A1HPGDCASP1HSD17B10
SCHEMBL14728711 0.84 PDE4B (0.63) PDE4BALDH1A1HPGDCASP1HSD17B10
SCHEMBL14728729 0.84 PDE4B (0.63) PDE4BALDH1A1HPGDCASP1HSD17B10
SCHEMBL14728731 0.84 PDE4B (0.63) PDE4BALDH1A1HPGDCASP1HSD17B10
SCHEMBL7712186 0.84 PDE4B (0.62) PDE4BALDH1A1HPGDCASP1HSD17B10
SCHEMBL14728719 0.83 PDE4B (0.61) PDE4BALDH1A1HPGDCASP1HSD17B10
SCHEMBL14728692 0.80 PDE4B (0.52) PDE4BALDH1A1HPGDCASP1HSD17B10
SCHEMBL14728689 0.77 PDE4B (0.51) PDE4BALDH1A1HPGDCASP1HSD17B10
SCHEMBL14716328 0.77 PDE4B (0.79) PDE4BALDH1A1HPGDCASP1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 US disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE PDE4B, PDE4A, PDE4C PDE4B 1/4885ALDH1A1 1070/4885HPGD 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.